Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 10/20 | 0.60 |
| ▸ | CTSG | P08311 | 8/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405682 | 0.91 | CMA1 (0.63) | CMA1CTSGACP3PTGER4MEN1 | |
| SCHEMBL4140309 | 0.85 | CMA1 (0.67) | CMA1CTSGACP3PTGER4MASP2 | |
| SCHEMBL1001231 | 0.81 | CMA1 (0.70) | CMA1CTSGACP3PTGER4CYP1A2 | |
| SCHEMBL409905 | 0.80 | CMA1 (0.59) | CMA1CTSGACP3KDM4E | |
| SCHEMBL998827 | 0.80 | CMA1 (0.68) | CMA1CTSGACP3PRSS1PRSS2 | |
| SCHEMBL10260984 | 0.78 | CMA1 (0.47) | CMA1CTSGACP3PTGER4MEN1 | |
| SCHEMBL1078569 | 0.78 | CTSG (0.75) | CMA1CTSGACP3PTGER4MASP2 | |
| SCHEMBL998839 | 0.77 | CTSG (0.58) | CMA1CTSGACP3MASP2 | |
| SCHEMBL3654937 | 0.76 | CMA1 (0.57) | CMA1CTSGACP3PTGER4MEN1 | |
| SCHEMBL4135674 | 0.76 | CMA1 (1.00) | CMA1CTSGACP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885CTSG 166/4885ACP3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.